China AML vs US Antitrust Law: Which Competition Law Approach?
Introduction
China’s Anti-Monopoly Law (AML) and United States antitrust law, which encompasses the Sherman Act of 1890, the Clayton Act of 1914, and the Federal Trade Commission Act, represent two distinct traditions in competition policy. US antitrust law is the oldest and most economically sophisticated antitrust system in the world, shaped by over 130 years of judicial precedent, the Chicago School’s emphasis on economic efficiency, and the more recent Harvard School’s focus on market structure and consumer harm. China’s AML, enacted in 2008, is a comparatively young legal framework that has undergone significant evolution, most notably through the 2022 amendments, and operates within a fundamentally different economic and political context.
For foreign businesses operating in both China and the United States, understanding the differences between these two regimes is not merely an academic exercise but a practical compliance necessity. Conduct that may pass muster under US antitrust law, particularly following the modern consumer welfare standard, may face more stringent scrutiny under China’s AML, and vice versa. This comparison analyzes the two systems across six dimensions: legal foundations, merger control, monopolization and abuse of dominance, horizontal and vertical agreements, enforcement mechanisms, and the role of industrial policy.
Legal foundations and enforcement architecture
US antitrust law is grounded in a common law tradition and is enforced through a dual system of public and private enforcement. The US Department of Justice (DOJ) Antitrust Division and the Federal Trade Commission (FTC) share federal enforcement authority, while state attorneys general can also bring antitrust actions. This decentralized enforcement model, combined with a robust system of private treble damages actions, creates multiple enforcement channels and significant deterrent effects. The federal courts serve as the ultimate arbiter of antitrust law, providing detailed economic analysis in published opinions that guide future conduct and enforcement policy.
China’s AML, by contrast, is a civil law statute enforced primarily through administrative processes. SAMR serves as the unified enforcement authority, with limited scope for private enforcement through the Chinese court system. The role of the courts in shaping competition policy in China is far less developed than in the US, and published decisions are fewer and less detailed. The administrative enforcement model gives SAMR broader discretion than US agencies and allows it to consider factors beyond competition analysis, including industrial policy objectives, social stability concerns, and alignment with national development strategies.
| Dimension | China AML | US Antitrust Law |
|---|---|---|
| Legal Tradition | Civil law (statutory, administrative enforcement) | Common law (judicial precedent, multiple enforcers) |
| Primary Statutes | Anti-Monopoly Law (2008, amended 2022) | Sherman Act (1890), Clayton Act (1914), FTC Act (1914) |
| Enforcement Agencies | SAMR (unified national authority) | DOJ Antitrust Division, FTC, state AGs |
| Private Enforcement | Limited; growing but still nascent | Robust; treble damages, class actions, discovery |
| Role of Courts | Limited; primarily administrative process | Central; courts shape law through precedent |
| Primary Enforcement Standard | Administrative discretion with policy alignment | Consumer welfare standard (since 1970s) |
Merger control: Thresholds, process, and substantive standards
Both China and the US require mandatory pre-merger notification for transactions that exceed specified thresholds, but the scope and nature of the review differ considerably. Under the Hart-Scott-Rodino (HSR) Act in the US, transactions must be notified if the value of the transaction exceeds a threshold that is adjusted annually (currently USD 119.5 million for the “size-of-transaction” test) and if the parties meet certain “size-of-person” thresholds. The review process is governed by strict statutory timelines: a 30-day initial waiting period, followed by a “second request” for additional information in cases that raise competitive concerns.
China’s AML merger control requires notification when global and Chinese turnover thresholds are met, as described in the previous article. The review process involves a 30-day preliminary review, a 90-day further review, and a potential 60-day extension. Unlike the US second request process, which has enforceable timelines, China’s “stop the clock” mechanism allows SAMR to suspend the review period indefinitely when parties fail to provide complete information, creating greater uncertainty about the duration of the review.
The substantive standards also differ. US merger review is focused on whether the transaction is likely to “substantially lessen competition” or “tend to create a monopoly,” analyzed through the lens of consumer welfare effects. The 2023 Merger Guidelines issued jointly by the DOJ and FTC emphasize market concentration, coordinated effects, and unilateral effects analysis, with a significant body of case law guiding the application of these standards. China’s AML applies a broader standard that includes not only competitive effects but also considerations such as the impact on national economic development, industrial policy objectives, and public interest. This broader mandate gives SAMR more flexibility to approve or block transactions on grounds that would not be cognizable under US antitrust law.
Monopolization versus abuse of dominance
The US prohibition on monopolization under Section 2 of the Sherman Act and China’s prohibition on abuse of dominance under Article 22 of the AML both target unilateral anti-competitive conduct by firms with market power, but the analytical frameworks differ. US monopolization law requires proof of two elements: (1) the possession of monopoly power in a relevant market, and (2) the willful acquisition or maintenance of that power through exclusionary conduct rather than through superior product, business acumen, or historical accident.
China’s AML establishes a rebuttable presumption of dominance at a 50 percent market share and prohibits abuse of dominance through specific categories of conduct: unfair pricing, predatory pricing, refusal to deal, exclusive dealing, tying and bundling, and discriminatory treatment. The test for each type of abuse is more formalistic than the US approach, with less emphasis on economic analysis of competitive effects. However, the 2022 amendments introduced clearer criteria for establishing abuse and expanded SAMR’s powers to investigate and penalize abusive conduct, signaling a more enforcement-oriented approach.
A significant divergence is the treatment of “excessive pricing.” US antitrust law is famously reluctant to police high prices, following the Supreme Court’s reasoning in Trinko (2004) that charging monopoly prices is an important element of the free market system, attracting competition through the profit motive. China’s AML, by contrast, expressly prohibits “unfairly high prices” charged by dominant firms, and SAMR has actively enforced this prohibition in sectors such as pharmaceuticals, chemicals, and public utilities. This difference reflects a broader philosophical divergence between the US consumer welfare standard and China’s emphasis on fairness and market order.
Horizontal and vertical agreements
The treatment of anti-competitive agreements is another area of significant divergence. US antitrust law applies the per se rule to “hardcore” horizontal restraints such as price fixing, output restrictions, and market allocation, meaning these agreements are considered automatically illegal without any inquiry into their competitive effects. Other horizontal agreements and most vertical agreements are assessed under the rule of reason, which requires a detailed analysis of competitive effects, market conditions, and potential justifications.
China’s AML similarly distinguishes between horizontal and vertical monopoly agreements but applies different analytical frameworks. Horizontal monopoly agreements (price fixing, output restrictions, market allocation, restrictions on new technology, and collective boycotts) are generally prohibited with limited exemptions available under Article 20, which requires parties to demonstrate that the agreement meets specific criteria, including that the agreement does not seriously restrict competition and that consumers share in the resulting benefits.
Vertical monopoly agreements have been a particularly dynamic area of divergence. The 2022 amendments to China’s AML introduced important changes: resale price maintenance (RPM) now benefits from a rebuttable presumption of illegality, rather than being treated as per se illegal as previously. This brings China closer to the US approach, where RPM has been assessed under the rule of reason since the Supreme Court’s Leegin decision in 2007. However, in practice, SAMR continues to scrutinize RPM aggressively, particularly in the automotive, pharmaceutical, and consumer goods sectors, and the rebuttable presumption often functions as a de facto prohibition in enforcement practice.
Enforcement mechanisms, penalties, and remedies
The enforcement tools available to US antitrust authorities are broader and more varied than under China’s AML. US agencies can seek criminal penalties for hardcore cartel conduct, including prison sentences for individuals (up to 10 years under the Sherman Act), as well as criminal fines for corporations. The DOJ actively prosecutes international cartels and has obtained record criminal fines exceeding USD 1 billion in individual cases. Civil enforcement includes injunctive relief, damages, and structural remedies such as divestiture.
China’s AML, prior to the 2022 amendments, provided for administrative fines only and lacked criminal sanctions for individuals. The 2022 amendments introduced the possibility of individual liability for monopoly agreements, including fines on legal representatives and directly responsible personnel of up to RMB 1 million. While these individual penalties are modest by US standards, they represent an important step toward personal accountability. China still does not impose criminal imprisonment for competition law violations, although the 2022 amendments included a provision referencing criminal liability for serious violations, which may signal future legislative development.
US private enforcement through treble damages actions is a powerful deterrent that has no equivalent in China. Under US law, private plaintiffs who have suffered antitrust injury can recover three times their actual damages plus reasonable attorneys’ fees and costs. This creates strong incentives for private enforcement and supplements public enforcement resources. China’s private antitrust litigation has grown since the adoption of the AML but remains limited in scope: damages are typically compensatory rather than punitive, discovery is restricted, and the success rate for plaintiffs is lower than in the US.
The role of industrial policy and non-competition considerations
Perhaps the most fundamental difference between China’s AML and US antitrust law is the role of industrial policy and other non-competition considerations in enforcement decisions. US antitrust law, particularly since the rise of the consumer welfare standard in the 1970s and 1980s, has largely excluded industrial policy considerations from merger review and antitrust enforcement. The DOJ and FTC focus on whether conduct harms consumers through higher prices, reduced output, lower quality, or diminished innovation, without regard to whether a transaction serves broader economic or industrial policy goals.
China’s AML explicitly incorporates industrial policy considerations. Article 1 states that the AML is enacted “for the purpose of preventing and stopping monopolistic conduct, protecting fair competition in the market, improving the efficiency of economic operations, safeguarding the interests of consumers and the public interest, and promoting the healthy development of the socialist market economy.” The reference to “public interest” and “socialist market economy” provides a legal basis for SAMR to consider factors beyond pure competition analysis. In practice, this means that transactions involving state-owned enterprises, companies in strategic sectors, or those that align with national development priorities such as the “Made in China 2025” initiative may receive more favorable treatment under China’s merger review process.
Key Difference: In the US, a transaction that enhances efficiency and benefits consumers is likely to be approved regardless of its broader economic or industrial implications. In China, the same transaction may be subject to conditions or even blocked if it does not align with national development objectives or if it raises concerns about foreign control over strategic assets.
Practical implications for cross-border businesses
For foreign businesses operating in both China and the United States, the divergence between the two competition law regimes creates several practical challenges:
- Anticipating different outcomes: A transaction that is cleared unconditionally by the US antitrust agencies may face conditions or be blocked by SAMR, and vice versa. Companies should prepare for divergent outcomes when planning cross-border transactions that require clearance in both jurisdictions.
- Different information requirements: The information required for HSR filing in the US differs substantially from the materials required for AML notification in China. Companies should prepare separate filing packages that address each jurisdiction’s specific requirements, including market definition approaches and competitive analysis frameworks.
- Compliance program divergence: An antitrust compliance program designed for US law may not adequately address AML risks, particularly concerning vertical restraints, abuse of dominance in regulated sectors, and interactions with competitors in industry associations. Companies should develop China-specific compliance modules that address the unique aspects of the AML.
- Investigation risk management: The procedures for SAMR investigations (which include dawn raids, document seizures, and lengthy administrative proceedings) differ from DOJ/FTC investigations (which include grand jury subpoenas, civil investigative demands, and federal court proceedings). Companies should maintain separate crisis management protocols for each jurisdiction.
- Monitoring enforcement trends: Both regimes are in a state of flux. The 2022 amendments to China’s AML marked the most significant revision of the law since its enactment, while US antitrust policy has experienced significant shifts with each administration, including the 2023 Merger Guidelines, increased enforcement against technology platforms, and growing calls for structural separation under the “neo-Brandeisian” movement.
Strategic Recommendation: Foreign businesses should engage separate antitrust counsel in China and the United States who have specific expertise in each jurisdiction. While global law firms can provide coordination, the substantive analysis, procedural requirements, and enforcement risks differ sufficiently to warrant jurisdiction-specific legal advice from local practitioners.
Conclusion
China’s AML and US antitrust law represent two distinct competition policy traditions that are converging on certain issues while diverging on others. The US consumer welfare standard, shaped by over a century of judicial precedent and economic analysis, provides greater predictability and a more economics-driven approach to antitrust enforcement. China’s AML, while adopting many of the formal structures of modern competition law, operates within a framework that allows for broader administrative discretion and the integration of industrial policy objectives.
For foreign businesses, neither approach is inherently superior, but each requires a tailored compliance strategy. Companies that treat the two regimes as interchangeable risk significant compliance gaps. The most effective approach recognizes that competition law in the US is primarily about protecting consumers through competitive markets, while competition law in China serves multiple objectives including economic efficiency, consumer protection, and the promotion of national development goals. Navigating these differences successfully requires informed judgment, local expertise, and a proactive approach to competition law compliance. As both regimes continue to evolve, foreign businesses should monitor developments closely and adapt their compliance strategies to reflect the changing enforcement landscape in each jurisdiction.
